Charles River’s shares declined 2.3% following the Q1 earnings, reflecting investor caution amid ongoing portfolio restructuring and a cautious outlook on margin expansion despite announced cost savings and strategic divestitures.

• Delivered $100 million in incremental cost savings this year above 2025 levels, targeting $300 million in annualized savings from recent initiatives.
• Completed acquisitions to secure non-human primates supply and enhance next-generation sequencing capabilities supporting biologics testing.
• Divested CDMO and Cell Solutions businesses, with additional European discovery site sales planned, focusing on core drug development testing strengths.
• Initiatives expected to contribute to future margin expansion, though near-term performance and guidance left the market hesitant.